CN102114026A - Ointment preparation for treating duck leg diseases and preparation method thereof - Google Patents
Ointment preparation for treating duck leg diseases and preparation method thereof Download PDFInfo
- Publication number
- CN102114026A CN102114026A CN2009102452252A CN200910245225A CN102114026A CN 102114026 A CN102114026 A CN 102114026A CN 2009102452252 A CN2009102452252 A CN 2009102452252A CN 200910245225 A CN200910245225 A CN 200910245225A CN 102114026 A CN102114026 A CN 102114026A
- Authority
- CN
- China
- Prior art keywords
- ointment
- duck leg
- treatment
- leg disease
- consumption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an ointment containing nano-scale gentamycin sulfate and cefaclor for treating duck leg diseases and a preparation method thereof. The main medicaments of the ointment preparation are nano-scale powder, the ointment preparation can be applied to skin directly, and has the advantages of strengthening the target effect of medicaments, convenient administration, quick absorption, direct achievement to deeper skin, strong sterilization, small side effect and the like. The ointment preparation can effectively treat the duck leg diseases due to duck leg infection caused by staphylococcus, pseudomonas aeruginosa and other bacteria, so that the ointment containing the nano-scale gentamycin sulfate and the cefaclor can sufficiently play the effect of the medicament when treating the duck leg diseases.
Description
Technical field
The invention belongs to the veterinary drug technical field, particularly a kind of ointment formulation for the treatment of the duck leg disease and preparation method thereof.
Background technology
Duck is the traditional category that China aquatic bird is cultured, and the present number of animals raised of China occupies first of the world, and the gross output value in aquatic bird industry every year surpasses 1,000 hundred million yuan, has become the new growth point that China peasant increases income.But, in meat kind of duck feeding and management process, usually because each side former thereby cause the multiple leg diseases of kind of duck.Generally begin morbidity at 60 ages in days, sickness rate can be up to 7%-15%, but mortality rate is not high, in laying period generation is arranged also, especially the later stage shank sickness rate of laying eggs can reach about 10%, high mortality because of leg diseases causes kind of a duck laying rate, rate of fertilization to descend and plant duck causes great economic loss to Producer.
Cause the duck leg diseases, its common cause has:
1, body weight is too big: plant duck at finishing period, because feeding coal is higher than the standard feeding coal during controlled feeding, cause build excessive and lipidosis is too many, plant the duck difficulty in walking, cause leg diseases;
2, nutrition is unbalanced, lacks calcium, phosphorus and vitamin D or other mineral: vitamin D, calcium, phosphorus are the important component parts that constitutes skeleton; Vitamin D can promote absorption and the conversion of Ca, P.Plant duck when finishing period lacks Ca, P and vitamin D, happiness is crouched, and it is unable to walk, and skeleton is frangible, and is crippled.With the drake copulation time, the easiest fracture of shank skeleton causes the unexpected wounded or disabled of duck;
3, environmental factors: summer, surface temperature was too high, can surpass 40 ℃ sometimes, add the influence of high temperature dampness, cause stress, form crippled.In addition, the foot bottom soft tissue too firmly also can be damaged in ground, causes soft tissue hyperplasia, joint deformity;
4, bacterial infection: staphylococcus aureus, bacillus pyocyaneus, streptococcus, pseudomonas all can cause arthroncus, crippled.Not tight when production area sterilization, feedstuff, drinking-water are subjected to germ contamination, and per os enters intestinal and infects, and arthritis is secondary infection; Especially raising the place has sharp-pointed article such as glass, iron nail or place injustice to cause when duck body skin abrasion, when scratching, and in the pathogenic bacteria intrusive body, inappropriate medication or treatment are not thorough during treatment, transfer to chronic, cause arthroncus, particularly secondly tarsal joint is knee joint, toe joint.Arthroncus during morbidity, palpation has hotness, sick just the part is softer, and hardening thereafter can not be stretched in the wrong, showing serious limping maybe can not walk about, and the duck leg disease that this reason causes also is modal, accounts for about 80% of duck leg disease sickness rate, does not still have effective medicine at this type of disease at present, ointment of the present invention has remarkable therapeutical effect at the duck leg disease that is caused by trauma infection contamination.
Cefaclor: this product is semisynthetic second generation cephalosporin, and streptococcus pneumoniae, micrococcus scarlatinae, staphylococcus, proteus mirabilis, escherichia coli and pneumobacillus, hemophilus influenza, gonorrhea diplococcus and anaerobe etc. are had good antibacterial activity.To the bacteriostatic activity that produces enzyme gold Portugal bacterium, A type Hemolytic streptococcus, Streptococcus viridans, staphylococcus epidermidis, proteus mirabilis
By force.Be mainly used in skin and soft tissue infection.
Gentamycin: produced by micromonospora, be a kind of multicomponent aminoglycoside antibiotics, molecular formula is C
47H
79O
17NH
4, molecular weight: 934.17, various gram-negative bacterias and gram-positive bacteria all there are good antibacterial action, act on stronger to bacillus pyocyaneus, golden Portugal bacterium.Temperature and acid, alkali are all stablized.Characteristics are to bacillus pyocyaneus, Bacillus proteus and penicillin resistant gold Fructus Vitis viniferae potent inhibitory action of tool all.About 80% of methicillin-sensitivity bacterial strain in the staphylococcus (comprising golden Portugal bacterium and coagulase negative staphylococcus) there is good antibacterial action.Gentamycin can directly act on the pathological changes part, and its valid density is increased, and plays the effect of rapid anti-inflammatory analgetic, has the effect that isolation, anti-tissue fluid are oozed out in addition.
Nanoscale gentamycin and nanoscale cefaclor relatively have targeting, slow-releasing, controllability, the hypotoxicity and intelligent that strengthens medicine in the potent antimicrobial while with general medicine; Increase stability of drug, high diffusibility and percutaneous permeability.Change film operative mechanism, increase the performance of medicine to drug effect in biomembranous permeability, the Transdermal absorption that helps medicine and the cell.On the other hand also can be by increasing contact area, extending contact time, improve bioavailability.
The duck leg disease does not have obvious effect with general disinfectant solution series products disinfection, also there is slow, the untrue shortcoming of targeting target of onset in oral series products, therefore for the kind duck that generally suffers from the duck leg disease, only do to eliminate and handle, morbidity mortality about 10% has caused enormous economic loss to the raiser, the compound ointment of nanoscale gentamycin of the present invention and cefaclor has the antimicrobial effect of Synergistic.Can enter subcutaneous tissue and skin corium plays a role by the skin rapid osmotic, through diseased region, the strong drug level height of drug release and penetrance, effectively sterilization has improved curative effect, instant effect, side effect is little, can promote local blood to flow simultaneously, accelerates the absorption of edema, and can promote the metabolism of connective tissue, thereby improve tissue regeneration and promote wound healing.Ointment clinical experimental stage of the present invention is used for the treatment of bacillary duck leg disease in the area, Sichuan, obtained ideal experiment effect, disease sites to the duck that suffers from the duck leg disease carries out three times on the early, middle and late one the treatment of smearing, can subside a swelling in 3-5 days, all can fully recover in 7-10 days, cure rate reaches more than 90%.And not influencing breeding ordinary production such as lay eggs after curing.
Summary of the invention
The object of the invention is to provide prescription of a kind of ointment that contains nanoscale gentamycin sulfate and cefaclor and preparation method thereof, in order to treatment duck leg disease, makes things convenient for administration, instant effect.
One aspect of the present invention relates to the prescription that sulfur acid gentamycin and cefaclor ointment are provided, and wherein principal agent is nanoscale gentamycin sulfate and cefaclor; Pharmaceutic adjuvant comprises transdermal enhancer, wetting agent, emulsifying agent, antiseptic, surfactant and purified water etc.
According to the present invention, transdermal enhancer in the described pharmaceutic adjuvant includes but not limited to a kind of or combination in laurocapram, dimethyl sulfoxine, ethyl acetate, propylene glycol, menthol, the limonene etc., be preferably menthol, consumption is 1.0%～3.0% (W/W), and optimum amount is 1.0%-1.5% (W/W).
According to the present invention, the wetting agent in the described pharmaceutic adjuvant includes but not limited to a kind of of glycerol, propylene glycol, vaseline, sorbitol, Palmic acid etc. or combination, is preferably the combination of glycerol, white vaseline, and the glycerol consumption is 10%-20% (W/W); The consumption of white vaseline is 20.0%-50.0% (W/W).
According to the present invention, emulsifying agent in the described pharmaceutic adjuvant comprises but is not limited to a kind of of sodium alkyl benzene sulfonate, anhydrous sorbitol, fatty acid ester, glycerol monostearate, alkyl sodium sulfate etc. or combination, be preferably the glycerol monostearate, consumption is for being 1.0-20.0% (V/V), and optimum amount is 10%～15% (V/V).
According to the present invention, antiseptic in the described pharmaceutic adjuvant includes but not limited to potassium sorbate, sodium benzoate, ethylparaben, propyl p-hydroxybenzoate etc., be preferably ethylparaben, consumption is 0.1%～2.0% (W/V), and optimum amount is 0.1%～1.0% (W/V).
According to the present invention, surfactant includes but not limited to a kind of of tween 80, PEG-400, stearic acid, benzalkonium bromide etc. or combination in the described pharmaceutic adjuvant, is preferably tween 80 and stearic combination, and the consumption of tween 80 is 1.0%-10.0% (W/V); Stearic acid dosage is 10.0%～30.0% (W/V).
The present invention relates to the processing technology that the ointment that contains nanoscale gentamycin sulfate and cefaclor is provided on the other hand, and it comprises the steps:
(1) earlier principal agent is dissolved in an amount of warm purified water successively, makes it fully dissolve mixing, stir solution A.
(2) transdermal enhancer, emulsifying agent, wetting agent are mixed in 70-80 ℃ of heating and melting in the water-bath, stir oil phase B.
(3) it is an amount of to get purified water, add the antiseptic heating for dissolving put cold after, add the surfactant mixing again, solution C.
(4) with solution C and B liquid mixing and emulsifying, in the time of 50 ℃, add solution A, be stirred to natural cooling and get ointment formulation.
Ointment of the present invention can enter subcutaneous tissue and skin corium plays a role by dermal osmosis, through diseased region, drug release and penetrance are stronger, the local drug concentration height, effectively sterilization improves curative effect, instant effect, side effect is little, promotes local blood to flow, and accelerates the absorption of edema, and can promote the metabolism of connective tissue, thereby improve tissue regeneration and promote wound healing.
The specific embodiment
Embodiment 1:
The prescription that contains the ointment of nanoscale gentamycin sulfate and cefaclor:
| Component | Consumption |
| Gentamycin sulfate | 5.0％(W/W) |
| Cefaclor | 3..0％(W/W) |
| Menthol | 1.0％(W/W) |
| Stearic acid | 20.0％(W/W) |
| White vaseline | 20.0％(W/W) |
| The glycerol monostearate | 12.0％(W/W) |
| Glycerol | 15.0％(W/W) |
| Tween 80 | 6.0％(W/W) |
| Ethylparaben | 0.2％(W/W) |
| Purified water | Add to 100% (W/W) |
Compound method:
(1) earlier nanoscale principal agent gentamycin sulfate, cefaclor are dissolved in an amount of warm purified water, make it fully dissolve mixing, stir solution A.
(2) menthol, glycerol stearic acid, glycerol, white vaseline are mixed, 70-80 ℃ of heating and melting in water-bath, stir oil phase B.
(3) it is an amount of to get purified water, add the ethylparaben heating for dissolving put cold after, add tween 80 and stearic acid mixing again, solution C.
(4) with solution C and B liquid mixing and emulsifying, in the time of 50 ℃, add solution A, be stirred to natural cooling and get ointment formulation.
Embodiment 2:
The prescription that contains the ointment of nanoscale gentamycin sulfate and cefaclor:
| Component | Consumption |
| Gentamycin sulfate | 8.0％(W/W) |
| Cefaclor | 2.0％(W/W) |
| Menthol | 1.5％(W/W) |
| Stearic acid | 20.0％(W/W) |
| White vaseline | 20.0％(W/W) |
| The glycerol monostearate | 12.0％(W/W) |
| Glycerol | 10.0％(W/W) |
| Tween 80 | 2.0％(W/W) |
| Ethylparaben | 0.2％(W/W)) |
| Purified water | Add to 100% (W/W) |
Compound method:
(1) earlier nanoscale principal agent gentamycin sulfate, cefaclor are dissolved in an amount of warm purified water, make it fully dissolve mixing, stir solution A.
(2) menthol, glycerol stearic acid, glycerol, white vaseline are mixed, 70-80 ℃ of heating and melting in water-bath, stir oil phase B.
(3) it is an amount of to get purified water, add the ethylparaben heating for dissolving put cold after, add tween 80 and stearic acid mixing again, solution C.
(4) with solution C and B liquid mixing and emulsifying, in the time of 50 ℃, add solution A, be stirred to natural cooling and get ointment formulation.
Claims (9)
1. ointment for the treatment of the duck leg disease is characterized in that described ointment is is principal agent with gentamycin sulfate and cefaclor, and in addition an amount of pharmaceutic adjuvant is made.
2. a kind of ointment for the treatment of the duck leg disease according to claim 1 is characterized in that being made up of following proportioning: nanoscale gentamycin sulfate 1.0%～10.0% (W/W), cefaclor 1.0%-5.0% (W/W)
3. a kind of ointment for the treatment of the duck leg disease according to claim 1 is characterized in that pharmaceutic adjuvant comprises transdermal enhancer, wetting agent, emulsifying agent, antiseptic, surfactant and purified water etc.
4. a kind of ointment for the treatment of the duck leg disease according to claim 3, it is characterized in that transdermal enhancer in the pharmaceutic adjuvant comprises a kind of or combination in laurocapram, dimethyl sulfoxine, ethyl acetate, propylene glycol, menthol, the limonene etc., be preferably menthol, consumption is 1%～3.0% (W/W), and optimum amount is 1.0%-1.5% (W/W).
5. a kind of ointment for the treatment of the duck leg disease according to claim 3, it is characterized in that wetting agent comprises a kind of of glycerol, propylene glycol, vaseline, sorbitol, Palmic acid etc. or combination in the pharmaceutic adjuvant, be preferably glycerol, white vaseline, the glycerol consumption is 10%-20% (W/W), and the consumption of white vaseline is 20.0%-50.0% (W/W).
6. a kind of ointment for the treatment of the duck leg disease according to claim 3, it is characterized in that emulsifying agent comprises a kind of of sodium alkyl benzene sulfonate, anhydrous sorbitol, fatty acid ester, glycerol monostearate, alkyl sodium sulfate etc. or combination in the pharmaceutic adjuvant, be preferably the glycerol monostearate, consumption is 1.0-20.0% (W/W), and optimum amount is 10%～15% (W/W).
7. a kind of ointment for the treatment of the duck leg disease according to claim 3, antiseptic comprises potassium sorbate, sodium benzoate, ethylparaben, propyl p-hydroxybenzoate in the pharmaceutic adjuvant, be preferably ethylparaben, consumption is 0.1%～2.0% (W/W), and optimum amount is 0.1%～1.0% (W/W).
8. according to the described a kind of ointment for the treatment of the duck leg disease of claim 3, surfactant comprises a kind of of tween 80, PEG-400, stearic acid, benzalkonium bromide etc. or combination in the pharmaceutic adjuvant, be preferably tween 80, stearic acid, the consumption of tween 80 is 1.0%-10.0% (W/W), and stearic acid dosage is 10.0%～30.0% (W/W).
9. according to the described a kind of ointment for the treatment of the duck leg disease of claim 1 to 8, it is characterized in that: preparation method may further comprise the steps:
A) earlier principal agent is dissolved in an amount of warm purified water successively, makes its abundant mixing dissolving, stir solution A.
B) transdermal enhancer, emulsifying agent, wetting agent are mixed, 70-80 ℃ of heating and melting in water-bath, stir oil phase B.
C) it is an amount of to get purified water, add the antiseptic heating for dissolving put cold after, add the surfactant mixing again, solution C.
D) with solution C and B liquid mixing and emulsifying, in the time of 50 ℃, add solution A, be stirred to natural cooling and get ointment formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102452252A CN102114026A (en) | 2009-12-31 | 2009-12-31 | Ointment preparation for treating duck leg diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102452252A CN102114026A (en) | 2009-12-31 | 2009-12-31 | Ointment preparation for treating duck leg diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102114026A true CN102114026A (en) | 2011-07-06 |
Family
ID=44213026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102452252A Pending CN102114026A (en) | 2009-12-31 | 2009-12-31 | Ointment preparation for treating duck leg diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102114026A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784102A (en) * | 2015-03-20 | 2015-07-22 | 成都汇智远景科技有限公司 | Ceftezole sodium ointment |
-
2009
- 2009-12-31 CN CN2009102452252A patent/CN102114026A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104784102A (en) * | 2015-03-20 | 2015-07-22 | 成都汇智远景科技有限公司 | Ceftezole sodium ointment |
| CN104784102B (en) * | 2015-03-20 | 2018-01-02 | 宋益兴 | Cefobutazine sodium ointment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1335425C (en) | Antiviral or antibacterial compound and method of use | |
| JP7148994B2 (en) | Bisphosphosingel preparation and its use | |
| CN102697784B (en) | Enrofloxacin injection for livestock and preparation method thereof | |
| US20120201904A1 (en) | Skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
| CA2535004C (en) | Topical veterinary compositions and methods for the treatment and prevention of infection | |
| CN101450055A (en) | Soluble powder for treating livestock and poultry bacterial infection and parasitic disease | |
| CN102824337B (en) | Compound chlorhexidine acetate gel for treating livestock endometritis, and preparation method thereof | |
| ES2769893T3 (en) | Formulations of volatile organic compounds that have antimicrobial activity | |
| CN103007258A (en) | Medical composition containing fish serine protease and antibacterial compound, and uses thereof | |
| CN101129409A (en) | Antimycotic externally used drug | |
| CN102114026A (en) | Ointment preparation for treating duck leg diseases and preparation method thereof | |
| CN112043817A (en) | Anti-mite composition and application thereof | |
| CN104906132B (en) | A kind of plaster for preventing and treating lamb stomatitis | |
| CN101199520A (en) | Beta-Lacetam anti-biotic compound dose for animal containing benemid | |
| US11285122B2 (en) | Volatile organic compound formulations having antimicrobial activity | |
| KR100438209B1 (en) | Complex antimicrobial composition based on carvacrol, thymol, and citral | |
| CN117815181B (en) | Hoof and mouth spray for cattle and sheep with foot rot and preparation method and application thereof | |
| CN102552304B (en) | Externally applied medicament for treating mite infection of pets | |
| AU2019351157A1 (en) | Volatile organic compound formulations having antimicrobial activity | |
| RU2282450C2 (en) | Method for treating purulent wounds in animals | |
| CN104055782A (en) | Bacteriostatic nourishing cream for skin | |
| RU2280458C1 (en) | Anti-inflammatory ointment | |
| CN114712355B (en) | Application of RHPS4 in preparation of medicines for inhibiting staphylococcus aureus and pseudomonas aeruginosa | |
| US20220218637A1 (en) | Volatile Organic Compound Formulations Having Antimicrobial Activity | |
| CN101306111A (en) | Medicaments for treating animal trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110706 |